img

Global Somatostatin Analogue Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Somatostatin Analogue Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Somatostatin analogues are drugs that stop your body from making too many hormones. Some neuroendocrine tumours (NETs) make large amounts of hormones that cause a group of symptoms called carcinoid syndrome. Somatostatin analogues are a possible treatment for people with carcinoid syndrome.
Due to the COVID-19 pandemic, the global Somatostatin Analogue Drug market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Octreotide accounting for % of the Somatostatin Analogue Drug global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Acromegaly segment is altered to an % CAGR throughout this forecast period.
The global key companies of Somatostatin Analogue Drug include Camurus AB, Chiasma, Ipsen Group, Boehringer Ingelheim International GmbH, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc. and Tarveda Therapeutics Inc., etc. In 2024, the global top five players had a share approximately % in terms of revenue.
The United States Somatostatin Analogue Drug market size was US$ million in 2024, while China size was US$ million. The proportion of the United States was % in 2024, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Somatostatin Analogue Drug landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Somatostatin Analogue Drug market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Somatostatin Analogue Drug market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Somatostatin Analogue Drug market. Readers of the report can become informed about current and future trends of the global Somatostatin Analogue Drug market and how they will impact market growth during the forecast period.



By Company


Camurus AB
Chiasma
Ipsen Group
Boehringer Ingelheim International GmbH
Eli Lilly & Co.
F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Tarveda Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.
Segment by Type
Octreotide
Lanreotide
Pasireotide

Segment by Application


Acromegaly
Neuroendocrine Tumor (NET)
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Somatostatin Analogue Drug in global and regional level.
Chapter 3Detailed analysis of Somatostatin Analogue Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Somatostatin Analogue Drug revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Somatostatin Analogue Drug Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 Octreotide
1.2.3 Lanreotide
1.2.4 Pasireotide
1.3 Market by Application
1.3.1 Global Somatostatin Analogue Drug Market Growth Rate by Application: 2018 VS 2024 VS 2034
1.3.2 Acromegaly
1.3.3 Neuroendocrine Tumor (NET)
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Somatostatin Analogue Drug Market Size (2018-2034)
2.2 Somatostatin Analogue Drug Market Size across Key Geographies Worldwide: 2018 VS 2024 VS 2034
2.3 Global Somatostatin Analogue Drug Market Size by Region (2018-2023)
2.4 Global Somatostatin Analogue Drug Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Somatostatin Analogue Drug Countries Ranking by Market Size
3 Somatostatin Analogue Drug Competitive by Company
3.1 Global Somatostatin Analogue Drug Revenue by Players
3.1.1 Global Somatostatin Analogue Drug Revenue by Players (2018-2023)
3.1.2 Global Somatostatin Analogue Drug Market Share by Players (2018-2023)
3.2 Global Somatostatin Analogue Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Somatostatin Analogue Drug Revenue
3.4 Global Somatostatin Analogue Drug Market Concentration Ratio
3.4.1 Global Somatostatin Analogue Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Somatostatin Analogue Drug Revenue in 2024
3.5 Global Key Players of Somatostatin Analogue Drug Head office and Area Served
3.6 Global Key Players of Somatostatin Analogue Drug, Product and Application
3.7 Global Key Players of Somatostatin Analogue Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Somatostatin Analogue Drug Breakdown Data by Type
4.1 Global Somatostatin Analogue Drug Historic Revenue by Type (2018-2023)
4.2 Global Somatostatin Analogue Drug Forecasted Revenue by Type (2024-2034)
5 Global Somatostatin Analogue Drug Breakdown Data by Application
5.1 Global Somatostatin Analogue Drug Historic Market Size by Application (2018-2023)
5.2 Global Somatostatin Analogue Drug Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Somatostatin Analogue Drug Revenue by Company (2021-2023)
6.2 North America Somatostatin Analogue Drug Revenue by Type (2018-2034)
6.3 North America Somatostatin Analogue Drug Revenue by Application (2018-2034)
6.4 North America Somatostatin Analogue Drug Revenue by Country (2018-2034)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Somatostatin Analogue Drug Revenue by Company (2021-2023)
7.2 Europe Somatostatin Analogue Drug Revenue by Type (2018-2034)
7.3 Europe Somatostatin Analogue Drug Revenue by Application (2018-2034)
7.4 Europe Somatostatin Analogue Drug Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Somatostatin Analogue Drug Revenue by Company (2021-2023)
8.2 Asia Pacific Somatostatin Analogue Drug Revenue by Type (2018-2034)
8.3 Asia Pacific Somatostatin Analogue Drug Revenue by Application (2018-2034)
8.4 Asia Pacific Somatostatin Analogue Drug Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Somatostatin Analogue Drug Revenue by Company (2021-2023)
9.2 Latin America Somatostatin Analogue Drug Revenue by Type (2018-2034)
9.3 Latin America Somatostatin Analogue Drug Revenue by Application (2018-2034)
9.4 Latin America Somatostatin Analogue Drug Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Somatostatin Analogue Drug Revenue by Company (2021-2023)
10.2 Middle East and Africa Somatostatin Analogue Drug Revenue by Type (2018-2034)
10.3 Middle East and Africa Somatostatin Analogue Drug Revenue by Application (2018-2034)
10.4 Middle East and Africa Somatostatin Analogue Drug Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Camurus AB
11.1.1 Camurus AB Company Details
11.1.2 Camurus AB Business Overview
11.1.3 Camurus AB Somatostatin Analogue Drug Products and Services
11.1.4 Camurus AB Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023)
11.1.5 Camurus AB Somatostatin Analogue Drug SWOT Analysis
11.1.6 Camurus AB Recent Development
11.2 Chiasma
11.2.1 Chiasma Company Details
11.2.2 Chiasma Business Overview
11.2.3 Chiasma Somatostatin Analogue Drug Products and Services
11.2.4 Chiasma Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023)
11.2.5 Chiasma Somatostatin Analogue Drug SWOT Analysis
11.2.6 Chiasma Recent Development
11.3 Ipsen Group
11.3.1 Ipsen Group Company Details
11.3.2 Ipsen Group Business Overview
11.3.3 Ipsen Group Somatostatin Analogue Drug Products and Services
11.3.4 Ipsen Group Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023)
11.3.5 Ipsen Group Somatostatin Analogue Drug SWOT Analysis
11.3.6 Ipsen Group Recent Development
11.4 Boehringer Ingelheim International GmbH
11.4.1 Boehringer Ingelheim International GmbH Company Details
11.4.2 Boehringer Ingelheim International GmbH Business Overview
11.4.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Products and Services
11.4.4 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023)
11.4.5 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug SWOT Analysis
11.4.6 Boehringer Ingelheim International GmbH Recent Development
11.5 Eli Lilly & Co.
11.5.1 Eli Lilly & Co. Company Details
11.5.2 Eli Lilly & Co. Business Overview
11.5.3 Eli Lilly & Co. Somatostatin Analogue Drug Products and Services
11.5.4 Eli Lilly & Co. Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023)
11.5.5 Eli Lilly & Co. Somatostatin Analogue Drug SWOT Analysis
11.5.6 Eli Lilly & Co. Recent Development
11.6 F. Hoffmann-La Roche Ltd.
11.6.1 F. Hoffmann-La Roche Ltd. Company Details
11.6.2 F. Hoffmann-La Roche Ltd. Business Overview
11.6.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Products and Services
11.6.4 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023)
11.6.5 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug SWOT Analysis
11.6.6 F. Hoffmann-La Roche Ltd. Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Somatostatin Analogue Drug Products and Services
11.7.4 Novartis AG Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023)
11.7.5 Novartis AG Somatostatin Analogue Drug SWOT Analysis
11.7.6 Novartis AG Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Details
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Somatostatin Analogue Drug Products and Services
11.8.4 Pfizer Inc. Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023)
11.8.5 Pfizer Inc. Somatostatin Analogue Drug SWOT Analysis
11.8.6 Pfizer Inc. Recent Development
11.9 Tarveda Therapeutics Inc.
11.9.1 Tarveda Therapeutics Inc. Company Details
11.9.2 Tarveda Therapeutics Inc. Business Overview
11.9.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Products and Services
11.9.4 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023)
11.9.5 Tarveda Therapeutics Inc. Somatostatin Analogue Drug SWOT Analysis
11.9.6 Tarveda Therapeutics Inc. Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Details
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Products and Services
11.10.4 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023)
11.10.5 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug SWOT Analysis
11.10.6 Teva Pharmaceutical Industries Ltd. Recent Development
12 Somatostatin Analogue Drug Market Dynamics
12.1 Somatostatin Analogue Drug Industry Trends
12.2 Somatostatin Analogue Drug Market Drivers
12.3 Somatostatin Analogue Drug Market Challenges
12.4 Somatostatin Analogue Drug Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Somatostatin Analogue Drug Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2024 VS 2034
Table 2. Key Players of Octreotide
Table 3. Key Players of Lanreotide
Table 4. Key Players of Pasireotide
Table 5. Global Somatostatin Analogue Drug Market Size Growth Rate by Application (US$ Million), 2018 VS 2024 VS 2034
Table 6. Global Somatostatin Analogue Drug Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2024 VS 2034
Table 7. Global Somatostatin Analogue Drug Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Somatostatin Analogue Drug Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 9. Global Somatostatin Analogue Drug Market Size of Top 10 Countries, 2018 VS 2024 VS 2034, (US$ Million)
Table 10. Global Somatostatin Analogue Drug Revenue by Players (2018-2023) & (US$ Million)
Table 11. Global Somatostatin Analogue Drug Market Share by Players (2018-2023)
Table 12. Global Top Somatostatin Analogue Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Somatostatin Analogue Drug as of 2024)
Table 13. Ranking of Global Top Somatostatin Analogue Drug Companies by Revenue (US$ Million) in 2024
Table 14. Global 5 Largest Players Market Share by Somatostatin Analogue Drug Revenue (CR5 and HHI) & (2018-2023)
Table 15. Global Key Players of Somatostatin Analogue Drug, Headquarters and Area Served
Table 16. Global Key Players of Somatostatin Analogue Drug, Product and Application
Table 17. Global Key Players of Somatostatin Analogue Drug, Date of Enter into This Industry
Table 18. Mergers & Acquisitions, Expansion Plans
Table 19. Global Somatostatin Analogue Drug Market Size by Type (2018-2023) & (US$ Million)
Table 20. Global Somatostatin Analogue Drug Revenue Market Share by Type (2018-2023)
Table 21. Global Somatostatin Analogue Drug Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 22. Global Somatostatin Analogue Drug Revenue Market Share by Type (2024-2034)
Table 23. Global Somatostatin Analogue Drug Market Size by Application (2018-2023) & (US$ Million)
Table 24. Global Somatostatin Analogue Drug Revenue Market Share by Application (2018-2023)
Table 25. Global Somatostatin Analogue Drug Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 26. Global Somatostatin Analogue Drug Revenue Market Share by Application (2024-2034)
Table 27. North America Somatostatin Analogue Drug Revenue by Company (2021-2023) & (US$ Million)
Table 28. North America Somatostatin Analogue Drug Revenue by Type (2018-2023) & (US$ Million)
Table 29. North America Somatostatin Analogue Drug Revenue by Type (2024-2034) & (US$ Million)
Table 30. North America Somatostatin Analogue Drug Revenue by Application (2018-2023) & (US$ Million)
Table 31. North America Somatostatin Analogue Drug Revenue by Application (2024-2034) & (US$ Million)
Table 32. North America Somatostatin Analogue Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 33. North America Somatostatin Analogue Drug Revenue by Country (2018-2023) & (US$ Million)
Table 34. North America Somatostatin Analogue Drug Revenue by Country (2024-2034) & (US$ Million)
Table 35. Europe Somatostatin Analogue Drug Revenue by Company (2021-2023) & (US$ Million)
Table 36. Europe Somatostatin Analogue Drug Revenue by Type (2018-2023) & (US$ Million)
Table 37. Europe Somatostatin Analogue Drug Revenue by Type (2024-2034) & (US$ Million)
Table 38. Europe Somatostatin Analogue Drug Revenue by Application (2018-2023) & (US$ Million)
Table 39. Europe Somatostatin Analogue Drug Revenue by Application (2024-2034) & (US$ Million)
Table 40. Europe Somatostatin Analogue Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 41. Europe Somatostatin Analogue Drug Revenue by Country (2018-2023) & (US$ Million)
Table 42. Europe Somatostatin Analogue Drug Revenue by Country (2024-2034) & (US$ Million)
Table 43. Asia Pacific Somatostatin Analogue Drug Revenue by Company (2021-2023) & (US$ Million)
Table 44. Asia Pacific Somatostatin Analogue Drug Revenue by Type (2018-2023) & (US$ Million)
Table 45. Asia Pacific Somatostatin Analogue Drug Revenue by Type (2024-2034) & (US$ Million)
Table 46. Asia Pacific Somatostatin Analogue Drug Revenue by Application (2018-2023) & (US$ Million)
Table 47. Asia Pacific Somatostatin Analogue Drug Revenue by Application (2024-2034) & (US$ Million)
Table 48. Asia-Pacific Somatostatin Analogue Drug Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 49. Asia Pacific Somatostatin Analogue Drug Revenue by Region (2018-2023) & (US$ Million)
Table 50. Asia Pacific Somatostatin Analogue Drug Revenue by Region (2024-2034) & (US$ Million)
Table 51. Latin America Somatostatin Analogue Drug Revenue by Company (2021-2023) & (US$ Million)
Table 52. Latin America Somatostatin Analogue Drug Revenue by Type (2018-2023) & (US$ Million)
Table 53. Latin America Somatostatin Analogue Drug Revenue by Type (2024-2034) & (US$ Million)
Table 54. Latin America Somatostatin Analogue Drug Revenue by Application (2018-2023) & (US$ Million)
Table 55. Latin America Somatostatin Analogue Drug Revenue by Application (2024-2034) & (US$ Million)
Table 56. Latin America Somatostatin Analogue Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 57. Latin America Somatostatin Analogue Drug Revenue by Country (2018-2023) & (US$ Million)
Table 58. Latin America Somatostatin Analogue Drug Revenue by Country (2024-2034) & (US$ Million)
Table 59. Middle East and Africa Somatostatin Analogue Drug Revenue by Company (2021-2023) & (US$ Million)
Table 60. Middle East and Africa Somatostatin Analogue Drug Revenue by Type (2018-2023) & (US$ Million)
Table 61. Middle East and Africa Somatostatin Analogue Drug Revenue by Type (2024-2034) & (US$ Million)
Table 62. Middle East and Africa Somatostatin Analogue Drug Revenue by Application (2018-2023) & (US$ Million)
Table 63. Middle East and Africa Somatostatin Analogue Drug Revenue by Application (2024-2034) & (US$ Million)
Table 64. Middle East and Africa Somatostatin Analogue Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 65. Middle East and Africa Somatostatin Analogue Drug Revenue by Country (2018-2023) & (US$ Million)
Table 66. Middle East and Africa Somatostatin Analogue Drug Revenue by Country (2024-2034) & (US$ Million)
Table 67. Camurus AB Company Details
Table 68. Camurus AB Business Overview
Table 69. Camurus AB Somatostatin Analogue Drug Product and Services
Table 70. Camurus AB Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023) & (US$ Million)
Table 71. Camurus AB Somatostatin Analogue Drug SWOT Analysis
Table 72. Camurus AB Recent Development
Table 73. Chiasma Company Details
Table 74. Chiasma Business Overview
Table 75. Chiasma Somatostatin Analogue Drug Product and Services
Table 76. Chiasma Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023) & (US$ Million)
Table 77. Chiasma Somatostatin Analogue Drug SWOT Analysis
Table 78. Chiasma Recent Development
Table 79. Ipsen Group Company Details
Table 80. Ipsen Group Business Overview
Table 81. Ipsen Group Somatostatin Analogue Drug Product and Services
Table 82. Ipsen Group Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023) & (US$ Million)
Table 83. Ipsen Group Somatostatin Analogue Drug SWOT Analysis
Table 84. Ipsen Group Recent Development
Table 85. Boehringer Ingelheim International GmbH Company Details
Table 86. Boehringer Ingelheim International GmbH Business Overview
Table 87. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product and Services
Table 88. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023) & (US$ Million)
Table 89. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug SWOT Analysis
Table 90. Boehringer Ingelheim International GmbH Recent Development
Table 91. Eli Lilly & Co. Company Details
Table 92. Eli Lilly & Co. Business Overview
Table 93. Eli Lilly & Co. Somatostatin Analogue Drug Product and Services
Table 94. Eli Lilly & Co. Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023) & (US$ Million)
Table 95. Eli Lilly & Co. Somatostatin Analogue Drug SWOT Analysis
Table 96. Eli Lilly & Co. Recent Development
Table 97. F. Hoffmann-La Roche Ltd. Company Details
Table 98. F. Hoffmann-La Roche Ltd. Business Overview
Table 99. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product and Services
Table 100. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023) & (US$ Million)
Table 101. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug SWOT Analysis
Table 102. F. Hoffmann-La Roche Ltd. Recent Development
Table 103. Novartis AG Company Details
Table 104. Novartis AG Business Overview
Table 105. Novartis AG Somatostatin Analogue Drug Product and Services
Table 106. Novartis AG Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023) & (US$ Million)
Table 107. Novartis AG Somatostatin Analogue Drug SWOT Analysis
Table 108. Novartis AG Recent Development
Table 109. Pfizer Inc. Company Details
Table 110. Pfizer Inc. Business Overview
Table 111. Pfizer Inc. Somatostatin Analogue Drug Product and Services
Table 112. Pfizer Inc. Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023) & (US$ Million)
Table 113. Pfizer Inc. Somatostatin Analogue Drug SWOT Analysis
Table 114. Pfizer Inc. Recent Development
Table 115. Tarveda Therapeutics Inc. Company Details
Table 116. Tarveda Therapeutics Inc. Business Overview
Table 117. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product and Services
Table 118. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023) & (US$ Million)
Table 119. Tarveda Therapeutics Inc. Somatostatin Analogue Drug SWOT Analysis
Table 120. Tarveda Therapeutics Inc. Recent Development
Table 121. Teva Pharmaceutical Industries Ltd. Company Details
Table 122. Teva Pharmaceutical Industries Ltd. Business Overview
Table 123. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product and Services
Table 124. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue in Somatostatin Analogue Drug Business (2018-2023) & (US$ Million)
Table 125. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug SWOT Analysis
Table 126. Teva Pharmaceutical Industries Ltd. Recent Development
Table 127. Somatostatin Analogue Drug Market Trends
Table 128. Somatostatin Analogue Drug Market Drivers
Table 129. Somatostatin Analogue Drug Market Challenges
Table 130. Somatostatin Analogue Drug Market Restraints
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Somatostatin Analogue Drug Product Picture
Figure 2. Global Somatostatin Analogue Drug Market Size by Type (US$ Million): 2018 VS 2024 VS 2034
Figure 3. Global Somatostatin Analogue Drug Market Share by Type: 2024 VS 2034
Figure 4. Octreotide Features
Figure 5. Lanreotide Features
Figure 6. Pasireotide Features
Figure 7. Global Somatostatin Analogue Drug Market Size by Application (US$ Million): 2018 VS 2024 VS 2034
Figure 8. Global Somatostatin Analogue Drug Market Share by Application: 2024 VS 2034
Figure 9. Acromegaly
Figure 10. Neuroendocrine Tumor (NET)
Figure 11. Others
Figure 12. Somatostatin Analogue Drug Report Years Considered
Figure 13. Global Somatostatin Analogue Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 14. Global Somatostatin Analogue Drug Market Size 2018-2034 (US$ Million)
Figure 15. Global Somatostatin Analogue Drug Market Size Market Share by Region: 2024 VS 2034
Figure 16. Global Somatostatin Analogue Drug Revenue Market Share by Region in 2018 VS 2024
Figure 17. Global Somatostatin Analogue Drug Revenue Market Share Forecast by Region (2024-2034)
Figure 18. Global Top 10 Somatostatin Analogue Drug Countries Ranking by Market Size (US$ Million) in 2024
Figure 19. Global Somatostatin Analogue Drug Market Size of Top 10 Countries, 2018 VS 2024 VS 2034, (US$ Million)
Figure 20. Global Somatostatin Analogue Drug Market Share by Players in 2024
Figure 21. Global Top Somatostatin Analogue Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Somatostatin Analogue Drug as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Somatostatin Analogue Drug Revenue in 2024
Figure 23. North America Somatostatin Analogue Drug Revenue Market Share by Company in 2024
Figure 24. North America Somatostatin Analogue Drug Revenue Market Share by Type (2018-2034)
Figure 25. North America Somatostatin Analogue Drug Revenue Market Share by Application (2018-2034)
Figure 26. North America Somatostatin Analogue Drug Revenue Share by Country (2018-2034)
Figure 27. United States Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 28. Canada Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 29. Europe Somatostatin Analogue Drug Revenue Market Share by Company in 2024
Figure 30. Europe Somatostatin Analogue Drug Revenue Market Share by Type (2018-2034)
Figure 31. Europe Somatostatin Analogue Drug Revenue Market Share by Application (2018-2034)
Figure 32. Europe Somatostatin Analogue Drug Revenue Share by Country (2018-2034)
Figure 33. Germany Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 34. France Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 35. U.K. Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 36. Italy Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 37. Russia Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 38. Asia Pacific Somatostatin Analogue Drug Revenue Market Share by Company in 2024
Figure 39. Asia Pacific Somatostatin Analogue Drug Revenue Market Share by Type (2018-2034)
Figure 40. Asia Pacific Somatostatin Analogue Drug Revenue Market Share by Application (2018-2034)
Figure 41. Asia Pacific Somatostatin Analogue Drug Revenue Share by Region (2018-2034)
Figure 42. China Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 43. Japan Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 44. South Korea Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 45. India Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Australia Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 47. China Taiwan Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Indonesia Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Thailand Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 50. Malaysia Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 51. Latin America Somatostatin Analogue Drug Revenue Market Share by Company in 2024
Figure 52. Latin America Somatostatin Analogue Drug Revenue Market Share by Type (2018-2034)
Figure 53. Latin America Somatostatin Analogue Drug Revenue Market Share by Application (2018-2034)
Figure 54. Latin America Somatostatin Analogue Drug Revenue Share by Country (2018-2034)
Figure 55. Mexico Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 56. Brazil Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 57. Argentina Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Middle East and Africa Somatostatin Analogue Drug Revenue Market Share by Company in 2024
Figure 59. Middle East and Africa Somatostatin Analogue Drug Revenue Market Share by Type (2018-2034)
Figure 60. Middle East and Africa Somatostatin Analogue Drug Revenue Market Share by Application (2018-2034)
Figure 61. Middle East and Africa Somatostatin Analogue Drug Revenue Share by Country (2018-2034)
Figure 62. Turkey Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 63. Saudi Arabia Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 64. UAE Somatostatin Analogue Drug Revenue (2018-2034) & (US$ Million)
Figure 65. Camurus AB Revenue Growth Rate in Somatostatin Analogue Drug Business (2018-2023)
Figure 66. Chiasma Revenue Growth Rate in Somatostatin Analogue Drug Business (2018-2023)
Figure 67. Ipsen Group Revenue Growth Rate in Somatostatin Analogue Drug Business (2018-2023)
Figure 68. Boehringer Ingelheim International GmbH Revenue Growth Rate in Somatostatin Analogue Drug Business (2018-2023)
Figure 69. Eli Lilly & Co. Revenue Growth Rate in Somatostatin Analogue Drug Business (2018-2023)
Figure 70. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Somatostatin Analogue Drug Business (2018-2023)
Figure 71. Novartis AG Revenue Growth Rate in Somatostatin Analogue Drug Business (2018-2023)
Figure 72. Pfizer Inc. Revenue Growth Rate in Somatostatin Analogue Drug Business (2018-2023)
Figure 73. Tarveda Therapeutics Inc. Revenue Growth Rate in Somatostatin Analogue Drug Business (2018-2023)
Figure 74. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Somatostatin Analogue Drug Business (2018-2023)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries